Next Science Limited FY22 Investor Presentation 2023

Next Science Limited presents its FY22 financial results and business overview as of February 28, 2023. The company develops proprietary XBIO technology to reduce biofilm-based infections across wound and surgical applications, with a TAM exceeding US$12.5 billion and 47 patents. The presentation outlines product distribution strategies, revenue growth of 462,000 episodes of care (+80% YoY), and expansion plans within the advanced wound care market.